Hexarelin

Hexarelin is a synthetic hexapeptide belonging to the growth hormone-releasing peptide (GHRP) class and is recognized as one of the most potent agonists of the ghrelin receptor (GHS-R1a). It was developed as a research tool to probe growth-hormone secretagogue pathways and related receptor systems. Beyond the GH axis, laboratory work has examined its interactions with cardiac tissue models. Hexarelin is supplied strictly for in-vitro and laboratory research use only.

Hexarelin binds the growth hormone secretagogue receptor GHS-R1a, the same receptor activated by endogenous ghrelin, thereby stimulating pathways that promote growth-hormone release in pituitary cell and related experimental systems. In cardiac research models it has also been shown to engage the scavenger receptor CD36, independent of GHS-R1a. These dual receptor interactions allow investigators to separate GH-axis effects from direct tissue-level signaling. Receptor occupancy and downstream second-messenger cascades are typically studied in isolated cells or tissue preparations.

Hexarelin is employed as a tool compound in growth-hormone axis research to characterize GHS-R1a-mediated GH secretion and feedback regulation. Parallel investigations focus on ghrelin-receptor and CD36-mediated signaling in cardiac tissue models, including cardiomyocyte and isolated-heart preparations. Additional work examines receptor desensitization and tachyphylaxis after repeated exposure in cell-based assays. These lines of inquiry remain confined to controlled laboratory systems.

In vitro and ex-vivo studies consistently demonstrate robust stimulation of growth-hormone release via GHS-R1a activation, often exceeding that of earlier GHRP analogues under comparable conditions. Cardiac tissue models have revealed CD36-dependent effects on cellular signaling and metabolic parameters distinct from pure GH-secretagogue activity. Repeated-application experiments document progressive receptor desensitization, informing study designs that require sustained or intermittent exposure. Findings are model-system specific and do not extend beyond research contexts.

Hexarelin is typically handled as a lyophilized peptide requiring reconstitution in appropriate research-grade diluents under sterile laboratory conditions. Investigators monitor peptide stability, storage temperature, and freeze-thaw cycles to preserve receptor-binding activity. Experimental protocols often incorporate controls for receptor desensitization when multi-dose or continuous-exposure designs are used. All work is restricted to qualified research settings; the compound is not intended for human or animal consumption.